1. |
Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin, 2012, 62(6): 394-399.
|
2. |
Kudo M, Kawamura Y, Hasegawa K, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer, 2021, 10(3): 181-223.
|
3. |
Song T. Recent advances in surgical treatment of hepatocellular carcinoma. Drug Discov Ther, 2015, 9(5): 319-330.
|
4. |
Wang YY, Zhong JH, Su ZY, et al. Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma. Br J Surg, 2016, 103(6): 725-734.
|
5. |
魏永健, 任龙飞, 张磊, 等. 术前血小板与淋巴细胞比值对肝癌切除术后患者预后价值的Meta分析. 中国普通外科杂志, 2021, 30(1): 44-54.
|
6. |
张瑜, 陈琨. 血小板4项参数联合血清AFP水平检测对乙型肝炎肝硬化肝癌的诊断价值研究. 国际检验医学杂志, 2020, 41(23): 2921-2924.
|
7. |
Dai T, Deng M, Ye L, et al. Prognostic value of combined preoperative gamma-glutamyl transpeptidase to platelet ratio and fibrinogen in patients with HBV-related hepatocellular carcinoma after hepatectomy. Am J Transl Res, 2020, 12(6): 2984-2997.
|
8. |
Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med, 1996, 15(4): 361-387.
|
9. |
Kramer AA, Zimmerman JE. Assessing the calibration of mortality benchmarks in critical care: The Hosmer-Lemeshow test revisited. Crit Care Med, 2007, 35(9): 2052-2056.
|
10. |
Huitzil-Melendez FD, Capanu M, O’Reilly EM, et al. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol, 2010, 28(17): 2889-2895.
|
11. |
于潇, 武国兵, 张爱斌, 等. 血小板在肝细胞癌发生发展中的作用. 临床肝胆病杂志, 2022, 38(6): 1426-1430.
|
12. |
杨思维, 张致远, 苏天昊, 等. 肝纤维化血清学模型预测HBV相关肝细胞癌经肝动脉化疗栓塞序贯射频消融后复发. 中国介入影像与治疗学, 2021, 18(8): 449-454.
|
13. |
董菁菁, 王允野, 刘昆, 等. γ-谷氨酰转肽酶和血小板比值指数对慢性乙型肝炎肝纤维化的诊断价值. 中华传染病杂志, 2017, 35(11): 670-674.
|
14. |
Kim JH, Kim JW, Seo JW, et al. Noninvasive tests for fibrosis predict 5-year mortality and hepatocellular carcinoma in patients with chronic hepatitis B. J Clin Gastroenterol, 2016, 50(10): 882-888.
|
15. |
梅宝富, 邓志锋, 郑兰, 等. γ-谷氨酰转肽酶和血小板比值对肝癌介入术后急性肝功能恶化的预测作用. 肝脏, 2021, 26(2): 175-178.
|
16. |
Kim MN, Lee JH, Chon YE, et al. Fibrosis-4, aspartate transaminase-to-platelet ratio index, and gamma-glutamyl transpeptidase-to-platelet ratio for risk assessment of hepatocellular carcinoma in chronic hepatitis B patients: comparison with liver biopsy. Eur J Gastroenterol Hepatol, 2020, 32(3): 433-439.
|
17. |
Kunutsor SK. Gamma-glutamyltransferase—friend or foe within? Liver Int, 2016, 36(12): 1723-1734.
|
18. |
郭鸿雁, 刘庆峰. γ-谷氨酰转肽酶、高尔基体蛋白73及甲胎蛋白检测对早期原发性肝癌的诊断价值. 癌症进展, 2019, 17(11): 1332-1334, 1350.
|
19. |
高海锋, 赵秋剑. 血清AFP、5’-NT和GGT联合检测在肝细胞癌早期诊断中的应用价值. 山西医科大学学报, 2015, 46(2): 115-118.
|
20. |
Zhang R, Guo H, Xu J, et al. Activated platelets inhibit hepatocellular carcinoma cell differentiation and promote tumor progression via platelet-tumor cell binding. Oncotarget, 2016, 7(37): 60609-60622.
|
21. |
尹天圣, 易亚阳, 毛熙贤, 等. 肝癌肝切除术后肝衰竭危险因素的Meta分析. 临床肝胆病杂志, 2014, 30(10): 1009-1014.
|
22. |
孙雅轩. 微血管侵犯与肝细胞癌预后的关系的临床研究. 长春: 吉林大学, 2017.
|
23. |
Lee DH. Editorial for “Nomogram predicting vessels encapsulating tumor clusters in hepatocellular carcinoma from preoperative gadoxetate-enhanced MRI: a multicenter study”. J Magn Reson Imaging, 2022 Oct 25. doi: 10.1002/jmri.28489.
|
24. |
赵杰, 焦宇文, 钱峻, 等. 肥胖症患者腹腔镜袖状胃切除术后体质量反弹的危险因素分析及列线图模型的构建. 中华胃肠外科杂志, 2022, 25(10): 913-920.
|